摘要
目的应用IMAC预处理方案观察自体外周血干细胞移植（APBSCT）治疗急性髓细胞白血病（AML）的疗效。方法用APBSCT治疗AML患者14例。预处理方案：IMAC。结果全部病例移植后造血重建，目前无病生存8例（57．1％），平均生存时间26（8～72）个月，无移植相关性死亡。结论IMAC预处理方案对AML是安全和有效的方案，预处理方案加入去甲氧柔红霉素有望提高总生存期。
Objective To investigate the effect of idarubicin to intensify the MAC （IMAC） as preparative regimen for autologous peripheral blood stem cell transplantation （APBSCT） in acute myeloid leukemia. Methods Fourteen patients with acute myeloid leukemia who underwent APBSCT were analysed. IMAC was used as preparative regimens. Results All patients were engrafted successfully. The disease-free survival could be seen in 8 cases （57.1%）, the median disease-free survival duration were 26（8-72） months and no treatment-related mortality was present. Conclusion This study suggested that addition of ldarubicin to the MAC preparative regimens was safe, effective and feasible for patients with acute myeloid leukemia, and may improve disease-free survival and overall survival.
出处
《白血病．淋巴瘤》
CAS
2009年第12期744-745,共2页
Journal of Leukemia & Lymphoma
关键词
外周血干细胞移植
白血病
粒细胞
急性
药物疗法
联合
Peripheral blood stem cell transplantation
Leukemia, myelocytic, acute
Drug therapy, combination
